The road to bioabsorbable stents: reaching clinical reality?
This article provides an overview of the evolution of revascularization devices since Grüntzig's initial introduction of balloon angioplasty in 1977. In-stent restenosis (ISR) is the major shortcoming of conventional (permanent-implant) stent therapy; even with the innovation and promising benefits of drug-eluting stents, management of ISR is very difficult. ISR is mainly caused by the interaction between the blood and the stent surface and a permanent mechanical irritation of the vascular tissue. Thus stenting technology has moved toward the development of temporary implants composed of biocompatible materials which mechanically support the vessel during the period of high risk for recoil and then completely biodegrade in the long term. Preclinical and first clinical experiences with bioabsorbable magnesium stents are discussed.
Erne
Paul
P
Division of Cardiology, Kantonsspital Luzern, Luzern 16 CH 6000, Switzerland. Paul.Erne@KSL.CH
Schier
Matthias
M
Resink
Therese J
TJ
D020341:Absorbable Implants; D003324:Coronary Artery Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D016503:Drug Delivery Systems; D006801:Humans; D007501:Iron; D008274:Magnesium; D011108:Polymers; D015607:Stents
D011108:Polymers; D007501:Iron; D008274:Magnesium